A total of 13 studies that met the criteria were selected, including 8 studies on the treatment of hematological malignancies with CD19 combined with CD22 CAR T-cell therapy and 5 studies on the treatment of hematological malignancies with CD19 combined with CD20 CAR T-cell therapy. The gene discussed is CD22; the disease is hematologic disorder.